Related Experiment Video
Updated: Apr 19, 2026
07:05
Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
Published on: September 10, 2018
6.6K
Comparative efficiency research (COMER): meta-analysis of cost-effectiveness studies.
Carlos Crespo1, Antonio Monleon, Walter Díaz
1Statistical Department, Facultat de Biologia, University of Barcelona, Avda Diagonal 645, 08028 Barcelona, Spain. ccrespo@ub.edu.
BMC Medical Research Methodology
|December 24, 2014
Summary
A new meta-analysis method, Comparative Efficiency Research (COMER), was developed for cost-effectiveness studies. COMER is validated and useful for health decision-makers.
Area of Science:
- Health Economics
- Biostatistics
- Meta-Analysis
Background:
- Cost-effectiveness analysis is crucial for healthcare decision-making.
- Existing meta-analysis methods may not adequately combine evidence from cost-effectiveness studies.
- A novel approach is needed to synthesize findings from comparative efficiency research.
Purpose of the Study:
- To develop and validate a new meta-analysis method for cost-effectiveness studies, termed Comparative Efficiency Research (COMER).
- To introduce a new metric, total incremental net benefit (TINB), for assessing cost-effectiveness.
- To evaluate the performance of COMER using copula distributions and simulated data.
Main Methods:
- Developed TINB using inverse variance weighting of incremental net benefits (INB).
- Utilized copula distributions to model the dependence between costs and quality-adjusted life years (QoL).
- Validated the COMER method using a Spanish observational study and simulated cohorts across different cost-effectiveness scenarios.
Main Results:
- The Frank copula demonstrated a good fit for modeling costs and QoL.
- The TINB metric accurately predicted cost-effectiveness, with theoretical INB falling within the confidence intervals of TINB.
- The TINB > 0 test showed significant results for cost-effective and dominant scenarios, even with small sample sizes.
Conclusions:
- Comparative Efficiency Research (COMER) is a valid and reliable meta-analysis tool for cost-effectiveness studies.
- The TINB metric provides a robust way to determine cost-effectiveness within a meta-analytic framework.
- COMER can assist health decision-makers in synthesizing evidence from multiple cost-effectiveness studies.
More Related Videos
Related Concept Videos
01:15Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
403
Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
403
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
582
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
582
01:20Comparing the Survival Analysis of Two or More Groups
728
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
728
01:12Hazard Ratio
740
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
740
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
221
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
221
01:20Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
398
Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
398